AT-12 PHASE 1/2 STUDY OF TH-302, INVESTIGATIONAL HYPOXIA-ACTIVATED PRODRUG, AND BEVACIZUMAB IN PATIENTS WITH BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA

BACKGROUND: Hypoxia is implicated in the pathogenesis of glioblastoma multiforme (GBM), and greater hypoxic burden is associated with poorer outcomes in GBM. Treatment with bevacizumab (BEV) may increase intratumoral hypoxia. An ongoing phase 1/2 study (NCT01403610) investigates safety and activity...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Brenner, Andrew, Floyd, John, Eng, Clarence, Kroll, Stew, Fichtel, Lisa, Gruslova, Aleksandra, Lodi, Alessia, Tiziani, Stefano
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2014
Ämnen:
Abstracts
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217789/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.12
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk